EXAS
- Exact Sciences Corporation
()
Overview
Company Summary
Exact Sciences Corporation (EXAS) is a biotechnology company that specializes in developing non-invasive screening and diagnostic tests for the early detection of various cancers, especially colorectal cancer. The company is focused on improving patient outcomes and enhancing the overall efficiency of cancer prevention.
One of Exact Sciences' key products is the Cologuard test, which is a non-invasive stool-based DNA test that screens for colorectal cancer. This test is highly accurate and has been approved by the U.S. Food and Drug Administration (FDA). It can detect colorectal cancer and pre-cancerous growths, known as adenomas, by identifying specific DNA markers in the stool.
The process of using Cologuard involves patients collecting a stool sample at home and sending it to Exact Sciences' lab for analysis. The results are then communicated to healthcare providers, who can use them to make informed decisions about further diagnostic testing or treatment options.
In addition to Cologuard, Exact Sciences is also involved in ongoing research and development efforts to expand its product portfolio. The company invests in technologies and tests that can detect cancers in their early stages, when they are usually most treatable.
Overall, Exact Sciences' mission is to eradicate colorectal cancer and other types of cancer through the implementation of efficient and accessible screening methods. By combining advanced technology with a patient-centered approach, the company aims to contribute to the early detection and prevention of cancer, ultimately saving lives and improving healthcare outcomes.